Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00874276 · ClinicalTrials.gov registry record · NA
Pharmacotoxicology of Trichloroethylene Metabolites
A NA study of Congenital Lactic Acidosis, sponsored by University of Florida.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT00874276 is a NA study of Congenital Lactic Acidosis that has completed, run by University of Florida. The registered enrollment target is 21 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00874276, a NA study of Congenital Lactic Acidosis, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
To establish the relationship between human MAAI haplotype and DCA and tyrosine metabolism. This aim test the postulates that MAAI haplotype determines, and thus can predict,1) dose-dependent DCA kinetics and biotransformation.
Conditions Studied
Interventions
- DRUG Dichloroacetate (DCA)
- GENETIC Genetic Marker on Chromosome 14q24.3
Study Locations (1)
Florida
- University of Florida Shands Hospital - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2009-08 |
| Est. Completion | 2012-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00874276
The ClinicalTrials.gov registry entry for NCT00874276 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Congenital Lactic Acidosis appearing as the primary indexed condition, and to 2 interventions - of which Dichloroacetate (DCA) is the first listed.
NCT00874276 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT00874276 about?
NCT00874276 is a clinical study titled "Pharmacotoxicology of Trichloroethylene Metabolites". To establish the relationship between human MAAI haplotype and DCA and tyrosine metabolism. This aim test the postulates that MAAI haplotype determines, and thus can predict,1) dose-dependent DCA kinetics and biotransformation.
What is the current status of trial NCT00874276?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2009-08. Estimated completion is 2012-11.
What conditions does trial NCT00874276 study?
This clinical trial studies the following conditions: Congenital Lactic Acidosis.
What interventions are being tested in trial NCT00874276?
The interventions under investigation include: Dichloroacetate (DCA) (DRUG), Genetic Marker on Chromosome 14q24.3 (GENETIC).
Who is sponsoring clinical trial NCT00874276?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00874276 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.